SCHEDULE: Deerfield Management Group Discloses 6.49% Stake in Cogent Biosciences

Deerfield Management and its affiliated entities have disclosed a beneficial ownership of 6.49% in Cogent Biosciences, Inc., totaling 9,053,118 shares of common stock.

Summary

• Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have filed a Schedule 13G regarding their beneficial ownership in Cogent Biosciences, Inc.
• The filing reports beneficial ownership of 9,053,118 shares of Common Stock in Cogent Biosciences, Inc.
• This stake represents 6.49% of the total class of securities.
• The reporting persons collectively hold shared voting and shared dispositive power over all 9,053,118 shares.
• The event requiring this filing occurred on July 7, 2025, with the filing submitted on July 11, 2025.
• The principal executive offices of Cogent Biosciences, Inc. are located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451.
• The business office for the reporting persons is 345 Park Avenue South, 12th Floor, New York, NY 10010.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment group like Deerfield Management in Cogent Biosciences is generally viewed positively, signaling investor confidence.

Positives

• A significant institutional investment group, Deerfield Management, has taken a substantial 6.49% stake in Cogent Biosciences, indicating confidence in the company's prospects.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, suggesting a passive, long-term investment strategy.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater stability and confidence in the stock, potentially attracting further investment.

Next Steps

• Deerfield Management Group will continue to monitor its investment in Cogent Biosciences, Inc.

Key Dates

Keywords

Cogent Biosciences, Deerfield Management, Schedule 13G, beneficial ownership, common stock, institutional investment, biotech, healthcare